RedHill Biopharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio1.20
P/S Ratio0.994.400.211.584.70
P/B Ratio-1.7013.88-0.2615.2321.80
Enterprise Value Ratios
EV/Revenue0.153.671.922.195.49
Profitability & Returns
Return on Equity (ROE)-8.60%-2.06%
Return on Assets (ROA)-0.37%-0.16%-0.16%-0.28%-0.31%
Return on Capital Employed (ROCE)2.93%-7.46%1.11%-0.81%-0.59%
Leverage & Solvency Ratios
Debt/Equity-0.080.57-2.549.896.27
Liquidity Ratios
Current Ratio0.540.810.431.090.96
Quick Ratio0.340.440.280.870.81
Efficiency Ratios
Asset Turnover0.390.070.360.470.51
Inventory Turnover0.790.452.584.638.78
Yield & Distribution Ratios
Earnings Yield-1.04%0.83%-5.60%-0.72%-0.25%
FCF Yield-1.18%-1.25%-2.30%-0.48%-0.16%
Buyback Yield-3.76%-3.20%-0.32%-0.28%-0.23%